Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 7/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GSR | P00390 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10884958 | 1.00 | KMT2A (0.36) | KMT2AALOX15BLMPMP22LTA4H | |
| SCHEMBL17724338 | 1.00 | KMT2A (0.36) | KMT2AALOX15BLMPMP22LTA4H | |
| Hydrochloric Acid SCHEMBL15466926 | 0.98 | LTA4H (0.35) | KMT2AALOX15BLMPMP22LTA4H | |
| Hydrochloric Acid SCHEMBL19305474 | 0.98 | LTA4H (0.35) | KMT2AALOX15BLMPMP22LTA4H | |
| Hydrochloric Acid SCHEMBL2250588 | 0.98 | LTA4H (0.35) | KMT2AALOX15BLMPMP22LTA4H | |
| Trifluoroacetic Acid SCHEMBL30300486 | 0.90 | KMT2A (0.34) | KMT2AALOX15BLMPMP22LTA4H | |
| SCHEMBL10046708 | 0.85 | SLC1A1 (0.35) | KMT2AALOX15BLMPMP22LTA4H | |
| SCHEMBL1654337 | 0.85 | LTA4H (0.43) | KMT2AALOX15BLMPMP22LTA4H | |
| SCHEMBL130831 | 0.85 | SLC1A1 (0.52) | KMT2AALOX15BLMPMP22SLC1A1 | |
| SCHEMBL172526 | 0.85 | SLC1A1 (0.52) | KMT2AALOX15BLMPMP22SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228475-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION | 2024-07-11 | — | — | US | claimed |
| EP-4359380-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL) METHYL)BENZYL) AMINO)ISOINDOLINE-1,3-DIONE | Celgene Corporation (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117425642-A | Preparation method of (S) -2- (2, 6-dioxopiperidine-3-yl) -4- ((2-fluoro-4- ((3-morpholinoazetidin-1-yl) methyl) benzyl) amino) isoindoline-1, 3-dione | 新基公司 | 2024-01-19 | — | — | CN | claimed |
| WO-2022271557-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL) METHYL)BENZYL) AMINO)ISOINDOLINE-1,3-DIONE | CELGENE CORPORATION (US) | 2022-12-29 | — | — | WO | claimed |
| CN-116917280-B | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4725553-A2 | SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL) BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098027-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-04-09 | — | — | US | disclosed |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4467143-B1 | METHOD FOR PREPARING 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-L-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-L-YL)-3-FLUOROBENZONITRILE | CELGENE CORP (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4699660-A2 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4688771-A1 | NOVEL FAK DEGRADER COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION. | 2010-04-15 | — | — | US | disclosed |
| US-7635700-B2 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| EP-2066656-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | CELGENE CORPORATION | 2008-07-03 | — | — | US | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |
| EP-0634998-B1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | disclosed |
| US-5525629-A | HYDROXAMIC ACID DERIVATIVES | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1996-06-11 | — | — | US | disclosed |
| WO-1993020047-A1 | HYDROXAMIC ACID BASED COLLAGENASE AND CYTOKINE INHIBITORS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098027-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD | MDH2, MDH1, GOT1 | KMT2A 2485/4885ALOX15 3956/4885BLM 4832/4885 |
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | CTTN, SRC, PTK2 | KMT2A 2950/4885ALOX15 4440/4885BLM 3268/4885 |
| US-20080161328-A1 | e.g. 3-(5-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)-PIPERIDINE-2,6-DIONE; cytokine (epidermal/fibroblast/endothelial/tumor necrosis growth factors) antagonist; antitumor, antiinflammatory agent, neurodegenerative diseases | FGF2, TNF, FGF1 | KMT2A 4212/4885ALOX15 2972/4885BLM 4421/4885 |
| US-20100093774-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | IL5, IL6, PGF | KMT2A 4830/4885ALOX15 1420/4885BLM 2944/4885 |
| US-20240228475-A1 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | AQP1, AQP3, ADH1C | KMT2A 834/4885ALOX15 3561/4885BLM 748/4885 |
| US-20260098028-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBZ, HBG2, HBB | KMT2A 2484/4885ALOX15 1420/4885BLM 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.